S'abonner

A randomized trial of standard vs restricted opioid prescribing following midurethral sling - 20/07/22

Doi : 10.1016/j.ajog.2022.05.010 
Jaime B. Long, MD a, , Brianne M. Morgan, BS b, Sarah S. Boyd, MD a, Matthew F. Davies, MD a, Allen R. Kunselman, MA c, Christy M. Stetter, BS c, Michael H. Andreae, MD d
a Department of Obstetrics and Gynecology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA 
b Penn State University College of Medicine, Hershey, PA 
c Department of Public Health Sciences, Penn State Health Milton S. Hershey Medical Center, Hershey, PA 
d Department of Anesthesiology, University of Utah Hospital, Salt Lake City, UT 

Corresponding author: Jaime B. Long, MD.

Abstract

Background

Postoperative opioid prescribing has historically lacked information crucial to balancing the pain control needs of the individual patient with our professional responsibility to judiciously prescribe these high-risk medications.

Objective

This study aimed to evaluate pain control, satisfaction with pain control, and opioid use among patients undergoing isolated midurethral sling randomized to 1 of 2 different opioid-prescribing regimens.

Study Design

Patients who underwent isolated midurethral sling placement from June 1, 2020, to November 22, 2021, were offered enrollment into this prospective, randomized, open-label, noninferiority clinical trial. Participants were randomized to receive either a standard prescription of ten 5-mg oxycodone tablets provided preoperatively (standard) or an opioid prescription provided only during patient request postoperatively (restricted). Preoperatively, all participants completed baseline demographic and pain surveys, including the 9-Question Central Sensitization Index, Pain Catastrophizing Scale, and Likert pain score (scale 0–10). The participants completed daily surveys for 1 week after surgery to determine the average daily pain score, number of opioids used, other forms of pain management, satisfaction with pain control, perception of the number of opioids prescribed, and need to return to care for pain management. The online Prescription Drug Monitoring Program was used to determine opioid filling in the postoperative period. The primary outcome was average postoperative day 1 pain score, and an a priori determined margin of noninferiority was set at 2 points.

Results

Overall, 82 patients underwent isolated midurethral sling placement and met the inclusion criteria: 40 were randomized to the standard arm, and 42 were randomized to the restricted group. Concerning the primary outcome of average postoperative day 1 pain score, the restricted arm (mean pain score, 3.9±2.4) was noninferior to the standard arm (mean pain score, 3.7±2.7; difference in means, 0.23; 95% confidence interval, −∞ to 1.34). Of note, 23 participants (57.5%) in the standard arm vs 8 participants (19.0%) in the restricted arm filled an opioid prescription (P<.001). Moreover, 18 of 82 participants (22.0%) used opioids during the 7-day postoperative period, with 10 (25.0%) in the standard arm and 8 (19.0%) in the restricted arm using opioids (P=.52). Of participants using opioids, the average number of tablets used was 3.4±2.3, and only 3 participants used ≥5 tablets. On a scale of 1=“prescribed far more opioids than needed” to 5=“prescribed far less opioids than needed,” the means were 1.9±1.0 in the standard arm and 2.7±1.0 in the restricted arm (P<.001).

Conclusion

Restricted opioid prescription was noninferior to standard opioid prescription in the setting of pain control and satisfaction with pain control after isolated midurethral placement. Participants in the restricted arm filled fewer opioid prescriptions than participants in the standard arm. On average, only 3.4 tablets were used by those that filled prescriptions in both groups. Restrictive opioid-prescribing practices may reduce unused opioids in the community while achieving similar pain control.

Le texte complet de cet article est disponible en PDF.

Key words : midurethral sling, opioids, postoperative care


Plan


 The authors report no conflict of interest.
 This trial was funded by an intramural grant. Study data were collected and managed using Research Electronic Data Capture (REDCap) electronic data capture tools hosted at Penn State Health Milton S. Hershey Medical Center and Penn State College of Medicine. This study received National Institutes of Health (NIH) funding for RedCap, which implies compliance with NIH public access policy.
 This study was registered on ClinicalTrials.gov (identifier: NCT04277975; NCT04277975). The clinical trial date of registration was on February 18, 2020. The date of initial participant enrollment was on June 1, 2020.
 Individual participant data will be available. All individual participant data collected during the trial and after deidentification will be shared. The study protocol will be available. Data will be available immediately after publication, and there will be no end date. Data are available indefinitely at Data in Brief.
 Cite this article as: Long JB, Morgan BM, Boyd SS, et al. A randomized trial of standard vs restricted opioid prescribing following midurethral sling. Am J Obstet Gynecol 2022;227:313.e1-9.


© 2022  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 227 - N° 2

P. 313.e1-313.e9 - août 2022 Retour au numéro
Article précédent Article précédent
  • Salpingo-oophorectomy or surveillance for ovarian endometrioma in asymptomatic premenopausal women: a cost-effectiveness analysis
  • Megan S. Orlando, Lauren A. Cadish, Jonathan P. Shepherd, Tommaso Falcone, Olivia H. Chang, Rosanne M. Kho
| Article suivant Article suivant
  • The association between surgeon subspecialty training and postoperative outcomes following surgery for pelvic organ prolapse
  • Kristina J. Warner, Oluwateniola Brown, C. Emi Bretschneider

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.